Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) ...

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...

The collaboration will drive cord blood-derived allogeneic CAR T-cell development. Singapore General Hospital (SGH) has ...

Then games like Halls of Torment bolted on a bit more ARPG stuff—things got slightly more measured, predictable, and I lost ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Anixa Biosciences (ANIX) announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its ...

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, ...

Laboratories International announced an agreement with Singapore General Hospital SGH to provide Current Good Manufacturing ...

Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including ...

This valuable work extends previous studies to convincingly show that the centromere-histone core contributes to force transduction through the kinetochore. The centromere mainly strengthens one of ...

Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...